Numerous investigations have indicated that increased FADS2 expression may play a role in NAFLD pathophysiology (Arendt et al., 2015; Chen et al., 2017; Walle et al., 2019). This evidence concerns the gene FADS2 and metabolic dysfunction-associated steatotic liver disease.